PURPOSE: Over the past four decades, allogeneic hematopoietic cell transplantation (alloHCT) has evolved as a curative modality for patients with hematologic diseases. This study describes changes in use, technique, and survival in a population-based cohort. PATIENTS AND METHODS: The study included 38,060 patients with hematologic malignancies or disorders who underwent first alloHCT in a US or Canadian center from 1994 to 2005 and were reported to the Center for International Blood and Marrow Transplant Research. RESULTS: AlloHCT as treatment for acute lymphoblastic (ALL) and myeloid leukemias (AML), myelodysplastic syndrome (MDS), and Hodgkin and non-Hodgkin lymphomas increased by 45%, from 2,520 to 3,668 patients annually. From 1994 to 2005, use of both peripheral (7% to 63%) [corrected] and cord blood increased (2% to 10%), whereas use of marrow decreased (90% to 27%). Despite a median age increase from 33 to 40 years and 165% [corrected] increase in unrelated donors for alloHCT, overall survival (OS) at day 100 significantly improved for patients with AML in first complete remission after myeloablative sibling alloHCT (85% to 94%; P < .001) and unrelated alloHCT (63% to 86%; P < .001); 1-year OS improved among those undergoing unrelated alloHCT (48% to 63%; P = .003) but not among those undergoing sibling alloHCT. Similar results were seen for ALL and MDS. Day-100 OS after cord blood alloHCT improved significantly from 60% to 78% (P < .001) for AML, ALL, MDS, and chronic myeloid leukemia. Use of reduced-intensity regimens increased, yielding OS rates similar to those of myeloablative regimens. CONCLUSION: Survival for those undergoing alloHCT has significantly improved over time. However, new approaches are needed to further improve 1-year OS.
PURPOSE: Over the past four decades, allogeneic hematopoietic cell transplantation (alloHCT) has evolved as a curative modality for patients with hematologic diseases. This study describes changes in use, technique, and survival in a population-based cohort. PATIENTS AND METHODS: The study included 38,060 patients with hematologic malignancies or disorders who underwent first alloHCT in a US or Canadian center from 1994 to 2005 and were reported to the Center for International Blood and Marrow Transplant Research. RESULTS: AlloHCT as treatment for acute lymphoblastic (ALL) and myeloid leukemias (AML), myelodysplastic syndrome (MDS), and Hodgkin and non-Hodgkin lymphomas increased by 45%, from 2,520 to 3,668 patients annually. From 1994 to 2005, use of both peripheral (7% to 63%) [corrected] and cord blood increased (2% to 10%), whereas use of marrow decreased (90% to 27%). Despite a median age increase from 33 to 40 years and 165% [corrected] increase in unrelated donors for alloHCT, overall survival (OS) at day 100 significantly improved for patients with AML in first complete remission after myeloablative sibling alloHCT (85% to 94%; P < .001) and unrelated alloHCT (63% to 86%; P < .001); 1-year OS improved among those undergoing unrelated alloHCT (48% to 63%; P = .003) but not among those undergoing sibling alloHCT. Similar results were seen for ALL and MDS. Day-100 OS after cord blood alloHCT improved significantly from 60% to 78% (P < .001) for AML, ALL, MDS, and chronic myeloid leukemia. Use of reduced-intensity regimens increased, yielding OS rates similar to those of myeloablative regimens. CONCLUSION: Survival for those undergoing alloHCT has significantly improved over time. However, new approaches are needed to further improve 1-year OS.
Authors: A Shimoni; I Hardan; N Shem-Tov; M Yeshurun; R Yerushalmi; A Avigdor; I Ben-Bassat; A Nagler Journal: Leukemia Date: 2006-02 Impact factor: 11.528
Authors: Mats Remberger; Malin Ackefors; Sofia Berglund; Ola Blennow; Göran Dahllöf; Aldona Dlugosz; Karin Garming-Legert; Jens Gertow; Britt Gustafsson; Moustapha Hassan; Zuzana Hassan; Dan Hauzenberger; Hans Hägglund; Helen Karlsson; Lena Klingspor; Gunilla Kumlien; Katarina Le Blanc; Per Ljungman; Maciej Machaczka; Karl-Johan Malmberg; Hanns-Ulrich Marschall; Jonas Mattsson; Richard Olsson; Brigitta Omazic; Darius Sairafi; Marie Schaffer; Britt-Marie Svahn; Petter Svenberg; Lisa Swartling; Attila Szakos; Michael Uhlin; Mehmet Uzunel; Emma Watz; Annika Wernerson; Agneta Wikman; Ann-Charlotte Wikström; Jacek Winiarski; Olle Ringdén Journal: Biol Blood Marrow Transplant Date: 2011-05-11 Impact factor: 5.742
Authors: Sergio A Giralt; Mukta Arora; John M Goldman; Stephanie J Lee; Richard T Maziarz; Philip L McCarthy; Kathleen A Sobocinski; Mary M Horowitz Journal: Br J Haematol Date: 2007-04-24 Impact factor: 6.998
Authors: Ginna G Laport; Brenda M Sandmaier; Barry E Storer; Bart L Scott; Monic J Stuart; Thoralf Lange; Michael B Maris; Edward D Agura; Thomas R Chauncey; Ruby M Wong; Stephen J Forman; Finn B Petersen; James C Wade; Elliot Epner; Benedetto Bruno; Wolfgang A Bethge; Peter T Curtin; David G Maloney; Karl G Blume; Rainer F Storb Journal: Biol Blood Marrow Transplant Date: 2008-02 Impact factor: 5.742
Authors: Michael A Pulsipher; Kenneth M Boucher; Donna Wall; Haydar Frangoul; Michel Duval; Rakesh K Goyal; Peter J Shaw; Ann E Haight; Michael Grimley; Stephan A Grupp; Morris Kletzel; Richard Kadota Journal: Blood Date: 2009-06-15 Impact factor: 22.113
Authors: S Fu; L Rybicki; D Abounader; S Andresen; B J Bolwell; R Dean; A Gerds; B K Hamilton; R Hanna; B T Hill; D Jagadeesh; M E Kalaycio; H D Liu; B Pohlman; R M Sobecks; N S Majhail Journal: Bone Marrow Transplant Date: 2015-07-20 Impact factor: 5.483
Authors: Lisa P Spees; Paul L Martin; Joanne Kurtzberg; Andre Stokhuyzen; Lauren McGill; Vinod K Prasad; Timothy A Driscoll; Suhag H Parikh; Kristin M Page; Richard Vinesett; Christopher Severyn; Anthony D Sung; Alan D Proia; Kirsten Jenkins; Mehreen Arshad; William J Steinbach; Patrick C Seed; Matthew S Kelly Journal: Biol Blood Marrow Transplant Date: 2018-11-24 Impact factor: 5.742